Purpose: Vision-threatening ocular inflammation can be a devastating complication of granulomatosis with polyangiitis (GPA). Here we performed a retrospective observational study to describe the safety and efficacy of treating scleritis and uveitis with either cyclophosphamide or rituximab in GPA. Methods: A chart review of patients diagnosed with GPA-associated scleritis or uveitis, treated with either cyclophosphamide or rituximab as the final therapy at our clinic, was conducted. A total of 1 year of follow-up visits was required for inclusion in the study. Results: Thirteen patients (19 eyes) suffering from GPA-associated scleritis and/or uveitis were identified. As the final therapy, rituximab was administered to 9 patients and cyclophosphamide to 4. Mean duration of follow-up was 55 months (range 16–23 months). Remission was observed in all patients. Three patients had a flare of scleritis after the completion of therapy, and they were restarted on their respective agents. One patient had a flare of retinal vasculitis during rituximab therapy. One patient on cyclophosphamide experienced transient leukopenia. No adverse side effects of rituximab were noted throughout the course of treatment. Conclusions: Cyclophosphamide and rituximab are safe and effective agents for controlling scleritis and uveitis associated with GPA, with eventual progression towards steroid-sparing remission.

Keywords:
Granulomatosis with polyangiitis, Cyclophosphamide, Rituximab, Scleritis, Uveitis
1.
Fahey JL, Leonard E, Churg J, Godman G: Wegener’s granulomatosis. Am J Med 1954; 17: 168–179.
2.
Godman GC, Churg J: Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol 1954; 58: 533–553.
3.
Ahmed M, Niffenegger JH, Jakobiec FA, Ben-Arie-Weintrob Y, Gion N, Androudi S: Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. Int Ophthalmol 2008; 28: 35–46.
4.
Iida T, Spaide RF, Kantor J: Retinal and choroidal arterial occlusion in Wegener’s granulomatosis. Am J Ophthalmol 2002; 133: 151–152.
5.
Raiji VR, Palestine AG, Parver DL: Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol 2009; 148: 946–950.
6.
Sainz de la Maza M, Jabbur NS, Foster CS: Severity of scleritis and episcleritis. Ophthalmology 1994; 101: 389–396.
7.
Gu J, Zhou S, Ding R, Aizezi W, Jiang A, Chen J: Necrotizing scleritis and peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Ophthalmol Ther 2013; 2: 99–111.
8.
Sainz de la Maza M, Foster CS, Jabbur NS: Scleritis associated with systemic vasculitic diseases. Ophthalmology 1995; 102: 687–692.
9.
Cocho L, Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Sainz-de-la-Maza M, Foster CS: Scleritis in patients with granulomatosis with polyangiitis (Wegener). Br J Ophthalmol 2016; 100: 1062–1065.
10.
Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C: Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor 2009; 3: 12–19.
11.
Kubaisi B, Abu Samra K, Foster CS: Granulomatosis with polyangiitis (Wegener’s disease): an updated review of ocular disease manifestations. Intractable Rare Dis Res 2016; 5: 61–69.
12.
Ebrahimiadib N, Modjtahedi BS, Roohipoor R, Anesi SD, Foster CS: Successful treatment strategies in granulomatosis with polyangiitis-associated peripheral ulcerative keratitis. Cornea 2016; 35: 1459–1465.
13.
Recillas-Gispert C, Serna-Ojeda JC, Flores-Suarez LF: Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s). Graefes Arch Clin Exp Ophthalmol 2015; 253: 2279–2284.
14.
Onal S, Kazokoglu H, Koc A, Yavuz S: Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm 2008; 16: 230–232.
15.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–2581.
16.
Cao JH, Oray M, Foster CS: Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol 2016; 166: 207–208.
17.
Foster CS, Chang PY, Ahmed AR: Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117: 861–869.
18.
Joshi L, Hamour S, Salama AD, Pusey CD, Lightman S, Taylor SR: Renal and ocular targets for therapy in Wegener’s granulomatosis. Inflamm Allergy Drug Targets 2009; 8: 70–79.
19.
Sainz de la Maza M, Tauber J, Foster CS: The Sclera. New York, Springer, 2012.
20.
Tervaert JW, Elema JD, Kallenberg CG: Clinical and histopathological association of 29-kD-ANCA and MPO-ANCA. APMIS Suppl 1990; 19: 35.
21.
Galor A, Thorne JE: Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am 2007; 33: 835–854.
22.
Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA: Ocular complications of Wegener’s granulomatosis. Ophthalmology 1983; 90: 279–290.
23.
Jabs DA, Mudun A, Dunn JP, Marsh MJ: Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130: 469–476.
24.
Thorne JE, Jabs DA: Ocular manifestations of vasculitis. Rheum Dis Clin North Am 2001; 27: 761–779.
25.
Sainz de la Maza M, Foster CS, Jabbur NS: Scleritis-associated uveitis. Ophthalmology 1997; 104: 58–63.
26.
Messmer EM, Foster CS: Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol 1999; 43: 379–396.
27.
Spalton DJ, Graham EM, Page NG, Sanders MD: Ocular changes in limited forms of Wegener’s granulomatosis. Br J Ophthalmol 1981; 65: 553–563.
28.
Foster CS, Forstot SL, Wilson LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253–1263.
29.
Langford CA, Talar-Williams C, Barron KS, Sneller MC: Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463–469.
30.
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310–317.
31.
Smith JR, Mackensen F, Rosenbaum JT: Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 2007; 3: 219–226.
32.
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36–44.
33.
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771–1780.
34.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221–232.
35.
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al; RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417–427.
36.
Martin F, Chan AC: Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004; 20: 517–527.
37.
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834–4840.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.